Glycoconjugates

Name
Glycoconjugates
Accession Number
DBCAT000084
Description

Carbohydrates covalently linked to a nonsugar moiety (lipids or proteins). The major glycoconjugates are glycoproteins, glycopeptides, peptidoglycans, glycolipids, and lipopolysaccharides. (From Biochemical Nomenclature and Related Documents, 2d ed; From Principles of Biochemistry, 2d ed)

Drugs
DrugDrug Description
Darbepoetin alfaA recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
ErythropoietinA recombinant form of human erythropoietin used to increase differentiation of progenitor cells to red blood cells in the treatment of anemia.
PegfilgrastimA recombinant human granulocyte colony stimulating factor used to stimulate the production of neutrophils and prevent febrile neutropenia or infections after myelosuppressive chemotherapy.
SargramostimA modified form of recombinant human granulocyte-macrophage colony stimulating factor used to increase immune cell production after myelosuppressive therapy or bone marrow transplant.
Drotrecogin alfaA form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII.
Alpha-1-proteinase inhibitorA purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency.
FilgrastimA form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
BleomycinA chemotherapy agent used to treat various malignancies, including head and neck malignancy, lymphoma, and testicular tumors, among others.
VancomycinA glycopeptide antibiotic used to treat severe but susceptible bacterial infections such as MRSA (methicillin-resistant Staphylococcus aureus) infections.
ThyroglobulinFor the treatment of hypothyroidism (deficiency in the production of thyroid hormone).
TU-514Not Available
PhosphoramidonNot Available
BalhimycinBalhimycin is a novel glycopeptide antibiotic.
OritavancinAn antibacterial agent used to treat acute bacterial skin and skin structure infections caused by susceptible Gram-positive bacteria.
EritoranInvestigated for use/treatment in sepsis and septicemia.
AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
RomiplostimA fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP).
LJP 1082Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.
Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
CefilavancinInvestigated for use/treatment in bacterial infection, skin infections/disorders, and staph bacterial infections.
Thrombomodulin AlfaInvestigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.
PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
PegdinetanibInvestigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
TeicoplaninFor the treatment of bacterial infections caused by susceptible microorganisms.
DalbavancinAn antibacterial used to treat acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible strains of Gram-positive bacteria.
Human C1-esterase inhibitorA C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.
E5531Investigated for use/treatment in sepsis and septicemia.
ThrombopoietinInvestigated for use/treatment in thrombocytopenia.
TG4010Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.
Methoxy polyethylene glycol-epoetin betaA synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease.
Gastric intrinsic factorIntrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic...
Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
Epoetin deltaEpoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.
UlinastatinUlinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.
KRN-7000KRN7000 has been used in trials studying the treatment of Lung Cancer, Chronic Hepatitis C, Hepatitis B, Chronic, Unspecified Adult Solid Tumor, Protocol Specific, and Prevention of GvHD in Patients...
SiagosideSiagoside has been investigated for the treatment of Parkinson Disease.
MuplestimMuplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in...
MolgramostimMolgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis.
TecemotideTecemotide has been used in trials studying the treatment of Prostate Cancer and Carcinoma, Non-Small-Cell Lung.
BalugrastimBalugrastim has been used in trials studying the treatment of Solid Tumors.
Bleomycin A6Bleomycin A6 has been used in trials studying the treatment of Squamous Cell Lung Cancer.
LenograstimThe drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. Lenograstim is indicated as a treatment to reduce the duration of...
Protein S humanA medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy.
LipegfilgrastimA medication used to reduce the duration of chemotherapy-induced neutropenia and incidence of febrile neutropenia in cytotoxic chemotherapy.
SulglicotideNot Annotated
MifamurtideA muramyl dipeptide derivative used to treat high grade, resectable, non-metastatic osteosarcoma after surgical resection.
Ceramide NPCeramide NP is a lipid molecule included in a group of lipid molecules called ceramides. Ceramides are major lipid components in the stratum corneum of the human skin. Ceramide 3...
Ceramide APNot Annotated
Ceramide NGNot Annotated
RivipanselRivipansel has been used in trials studying the other, basic science, and treatment of Pain Crisis, Renal impairment, Anemia, Sickle Cell, Sickle Cell Disease, and Sickle Cell Disorders, among others.
RegramostimInvestigated for use/treatment in adverse effects (chemotherapy) and bone marrow transplant.
PRM-151PRM-151 is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis).
Recombinant CD40-ligandRecombinant CD40-ligand is under investigation in clinical trial NCT00053391 (Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma).
LeridistimLeridistim is under investigation in clinical trial NCT00004215 (Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia).
FibronectinFibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).
AvidinAvidin is under investigation in clinical trial NCT00345618 (Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach).
AlefaceptA recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
Contulakin-GInvestigated for use/treatment in pain (acute or chronic).
TelavancinAn antibacterial agent used in the treatment of complicated skin and skin structure infections and types of hospital-acquired bacterial pneumonia.
SOR-C13SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).
Talactoferrin alfaInvestigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.
Drugs & Drug Targets
DrugTargetType
Darbepoetin alfaErythropoietin receptortarget
ErythropoietinErythropoietin receptortarget
PegfilgrastimGranulocyte colony-stimulating factor receptortarget
PegfilgrastimNeutrophil elastaseenzyme
SargramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
SargramostimBone marrow proteoglycantarget
SargramostimInterleukin-3 receptor subunit alphatarget
SargramostimCytokine receptor common subunit betatarget
SargramostimSyndecan-2target
Drotrecogin alfaCoagulation factor VIIItarget
Drotrecogin alfaCoagulation factor Vtarget
Drotrecogin alfaPlasminogen activator inhibitor 1target
Drotrecogin alfaThrombomodulintarget
Drotrecogin alfaVitamin K-dependent protein Starget
Drotrecogin alfaProthrombintarget
Drotrecogin alfaPlatelet factor 4target
Drotrecogin alfaPlasma serine protease inhibitortarget
Drotrecogin alfaSerpin B6target
Drotrecogin alfaEndothelial protein C receptortarget
Alpha-1-proteinase inhibitorNeutrophil elastasetarget
FilgrastimGranulocyte colony-stimulating factor receptortarget
FilgrastimNeutrophil elastasetarget
BleomycinDNA ligase 3target
BleomycinDNA ligase 1target
BleomycinDNAtarget
BleomycinBleomycin hydrolaseenzyme
VancomycinD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycantarget
VancomycinSerum albumincarrier
Vancomycinalpha1-acid glycoproteincarrier
VancomycinHistamine H1 receptorcarrier
TU-514UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylasetarget
PhosphoramidonNeprilysintarget
PhosphoramidonKell blood group glycoproteintarget
OritavancinCytochrome P450 3A4enzyme
OritavancinCytochrome P450 2D6enzyme
OritavancinCytochrome P450 2C9enzyme
OritavancinCytochrome P450 2C19enzyme
OritavancinSerum albumincarrier
OritavancinPeptidoglycan precursorstarget
OritavancinBacterial cell wall peptide bridging segmentstarget
OritavancinPentaglycyl bridging segmenttarget
EritoranToll-like receptor 4target
RomiplostimThrombopoietin receptortarget
LJP 1082Beta-2-glycoprotein 1target
Thrombomodulin AlfaCoagulation factor Vtarget
Thrombomodulin AlfaProthrombintarget
PRO-542Free fatty acid receptor 4target
PegdinetanibVascular endothelial growth factor receptor 2target
TeicoplaninD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycantarget
DalbavancinD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycantarget
Human C1-esterase inhibitorComplement C1r subcomponenttarget
Human C1-esterase inhibitorComplement C1s subcomponenttarget
Human C1-esterase inhibitorPlasma kallikreintarget
Human C1-esterase inhibitorCoagulation factor XIItarget
Human C1-esterase inhibitorProthrombintarget
Human C1-esterase inhibitorCoagulation factor XItarget
Human C1-esterase inhibitorTissue-type plasminogen activatortarget
E5531Toll-like receptor 4target
ThrombopoietinThrombopoietin receptortarget
TG4010Mucin-1target
TG4010Interleukin-2target
Methoxy polyethylene glycol-epoetin betaErythropoietin receptortarget
Protein CCoagulation factor Vtarget
Protein CCoagulation factor VIIItarget
LenograstimGranulocyte colony-stimulating factor receptortarget
Protein S humanCoagulation factor Vtarget
Protein S humanCoagulation factor Xtarget
Protein S humanVitamin K-dependent protein Ctarget
LipegfilgrastimGranulocyte colony-stimulating factor receptortarget
MifamurtideToll-like receptor 4target
MifamurtideNucleotide-binding oligomerization domain-containing protein 2target
RegramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
RegramostimGM-CSF receptor alpha subunittarget
RegramostimCholinesteraseenzyme
AlefaceptT-cell surface antigen CD2target
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Contulakin-GVoltage-dependent N-type calcium channel subunit alpha-1Btarget